1. Home
  2. BUR vs MDXG Comparison

BUR vs MDXG Comparison

Compare BUR & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burford Capital Limited

BUR

Burford Capital Limited

HOLD

Current Price

$4.50

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo MiMedx Group Inc

MDXG

MiMedx Group Inc

HOLD

Current Price

$3.61

Market Cap

530.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUR
MDXG
Founded
2009
2006
Country
Guernsey
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
530.2M
IPO Year
2017
2007

Fundamental Metrics

Financial Performance
Metric
BUR
MDXG
Price
$4.50
$3.61
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$13.58
$9.00
AVG Volume (30 Days)
3.0M
1.7M
Earning Date
05-06-2026
04-29-2026
Dividend Yield
2.58%
N/A
EPS Growth
N/A
14.29
EPS
N/A
N/A
Revenue
$413,360,000.00
$418,630,000.00
Revenue This Year
$104.62
N/A
Revenue Next Year
N/A
$13.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.99
52 Week Low
$3.59
$3.03
52 Week High
$14.61
$7.99

Technical Indicators

Market Signals
Indicator
BUR
MDXG
Relative Strength Index (RSI) 41.50 49.42
Support Level $4.42 $3.45
Resistance Level $4.97 $7.39
Average True Range (ATR) 0.28 0.12
MACD 0.02 0.04
Stochastic Oscillator 21.50 51.43

Price Performance

Historical Comparison
BUR
MDXG

About BUR Burford Capital Limited

Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: